NGS reagent kit AVENIO ctDNA Expanded V2

FFPE tissuesfor cancersfor cfDNA

The AVENIO ctDNA Expanded Kit V2 is a next-generation sequencing (NGS) liquid biopsy research assay with a 77 gene panel containing genes in U.S. National Comprehensive Cancer Network (NCCN) Guidelines1 and emerging cancer biomarkers. It is a pan-cancer assay that’s specially optimized for lung cancer and colorectal cancer (CRC) research. Benefits at a glance Exceptional analytical performance The analytical performance is supported by integrated digital error suppression (iDES) strategies combining molecular barcodes with in silico error suppression techniques. Benefits at a glance Exceptional analytical performance Target with tick icon, illustrating the exceptional performance of the AVENIO ctDNA Expanded Kit V2 The analytical performance is supported by integrated digital error suppression (iDES) strategies combining molecular barcodes with in silico error suppression techniques.2,3 Streamlined workflow The end-to-end research workflow is streamlined across five days, from extraction to analysis and reporting. Comprehensive research Test a wide range of genes and mutation classes in a single, comprehensive assay. 77 genes, including genes from the U.S. National Comprehensive Cancer Network (NCCN) Guidelines1 and emerging cancer biomarkers All four mutation classes (SNVs, indels, fusions, and CNVs) in a single assay